Amy Abernethy, MD, PhD
Chief Medical Officer, Chief Scientific Officer & Senior Vice President, Oncology
New York, NY
Dr. Amy Abernethy serves as Chief Medical Officer, Chief Scientific Officer and Senior Vice President, Oncology, where she leads the research oncology, clinical operations and data science teams, and contributes to the strategic vision of Flatiron Health.
Before joining Flatiron, Amy was Professor of Medicine at Duke University School of Medicine and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which aggregated clinical data can support personalized medicine, outcomes research, cancer care quality monitoring, and scientific discovery. Flatiron is a hyper-growth health technology company that started in 2012 and was acquired by Roche Group in 2018 for $2.1 billion.
With over 400 peer-reviewed publications, Amy is an internationally-recognized expert in clinical trials, cancer outcomes research, health policy, health services research, patient reported outcomes, clinical informatics and patient-centered care. She maintains a close affiliation with Duke and is a member of the National Academy of Medicine’s National Cancer Policy Forum, past President of the American Academy of Hospice & Palliative Medicine, recent member of the Board of Directors for the Personalized Medicine Coalition, and recent leader within several federally-funded research networks. She also serves on the Board of Directors for athenahealth (NASDAQ: ATHN) and CareDx (NASDAQ: CDNA) and advises several early-stage health technology companies (SignalPath, Inc; The One Health Company; RobinCare).
Amy received her MD at Duke University, where she also did her internal medicine residency, served as chief resident and completed her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine and clinical informatics, and her Bachelor's degree from the University of Pennsylvania.
The Cancer Prevention and Control Colloquia Series features current research findings from guest researchers from a variety of research disciplines. Topics cover current challenges and methods used by investigators to address gaps, advance the field of cancer prevention and control, and promote the application of successful strategies.